Milgram
Benjamin Charles Milgram, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20160046626 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS - The present invention provides compounds of Formula I, | 02-18-2016 |
K. Eric Milgram, Limerick, PA US
Patent application number | Description | Published |
---|---|---|
20090179147 | SYSTEMS, METHODS, AND COMPUTER-READABLE MEDIUM FOR DETERMINING COMPOSITION OF CHEMICAL CONSTITUENTS IN A COMPLEX MIXTURE - Systems, methods, and computer-readable media for determining composition of chemical constituents in a complex mixture are disclosed. According to one aspect, a method for determining composition of chemical constituents in a complex mixture includes generating, using a separation tool and a mass spectrometer, separation and mass spectrometry data of a sample, wherein the separation data includes peak information and wherein the mass spectrometry data includes primary and secondary mass spectrometry data. The analysis results, including the generated separation and mass spectrometry data, are collected and stored. A chemical constituent of the sample is determined by comparing the analysis results to a library of information indicating characteristics of chemical entities, where the comparison is based on the separation and mass spectrometry information. The library of information includes data generated by the separation tool and mass spectrometer, and also includes separation and mass spectrometry data for both identified and unidentified chemical entities. An indication of the chemical constituent of the sample is made available in human-accessible form. | 07-16-2009 |
Norton W. Milgram, Toronto CA
Patent application number | Description | Published |
---|---|---|
20150344413 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS - The present application relates to novel compounds comprising a moiety that leads to the metabolic production of ketones bonded to a ketone-potentiated anti-epileptic drug, compositions comprising these compounds, and their use, for example for the treatment of epilepsy, and other CNS diseases, disorders or conditions. In particular, the present application includes compounds of Formula I, and compositions and uses thereof: | 12-03-2015 |
Paul Milgram, Toronto CA
Patent application number | Description | Published |
---|---|---|
20110172519 | SYSTEMS, DEVICES AND METHODS EMPLOYING FIBER OPTIC SHAPE TRACKING - The present invention provides systems, devices, and methods employing fiber optic shape and position tracking. The systems, devices, and methods permit measurement of and continuous tracking of the shape and position of objects whose shape dynamically changes with time. Applications include tracking and monitoring of endoscopes for diagnostic and surgical procedures. | 07-14-2011 |
20120259211 | SYSTEMS, DEVICES, AND METHODS EMPLOYING FIBER OPTIC SHAPE TRACKING - The present invention provides systems, devices, and methods employing fiber optic shape and position tracking. The systems, devices, and methods permit measurement of and continuous tracking of the shape and position of objects whose shape dynamically changes with time. Applications include tracking and monitoring of endoscopes for diagnostic and surgical procedures. | 10-11-2012 |
Sarah Milgram, Moretel Des Mailles FR
Patent application number | Description | Published |
---|---|---|
20130137085 | Method for Real-Time Measurement of the Individual Secretions of a Cell - The present invention relates to a method for real-time measurement of the secretion of at least one compound by at least one individual cell, comprising: | 05-30-2013 |
William Milgram, Toronto CA
Patent application number | Description | Published |
---|---|---|
20090081626 | System and method for assessing cognitive function and measuring treatment efficacy - Embodiments of the invention described herein relate generally to a method for assessing cognitive function and measuring treatment efficacy. Assessing the efficacy of clinical treatments is important for development of new interventions, for example drugs, gene, protein or antibody therapies, as well as for monitoring patient responses to approved and prescribed therapies. It is feasible to use modified versions of tests developed for experimental animals, such as primates or canines, to evaluate cognition in humans. Because the tasks are non-verbal, individuals with severely limited cognitive abilities can be objectively evaluated. Inferences can be made about the human neuropathology because the neural substrates underlying the ability to perform these tasks in animals have been delineated. | 03-26-2009 |